|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Parkin DM, Piñeros M, Znaor A and Bray F: Cancer statistics for the
year 2020: An overview. Int J Cancer. 149:778–789. 2021. View Article : Google Scholar
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cancer registry annual report, 2021
Taiwan, Department of Health, Executive Yuan. https://www.hpa.gov.tw/File/Attach/17639/File_23506.pdfFebruary
25–2024
|
|
4
|
NCCN, . The NCCN Clinical Practice
Guidelines in Oncology (NCCN Guidelines®). 2024.version
1.0.https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1453Febuary
25–2024
|
|
5
|
Burger RA, Brady MF, Bookman MA, Fleming
GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE,
et al: Incorporation of bevacizumab in the primary treatment of
ovarian cancer. N Engl J Med. 365:2473–2483. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moore K, Colombo N, Scambia G, Kim BG,
Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke
GS, et al: Maintenance olaparib in patients with newly diagnosed
advanced ovarian cancer. N Engl J Med. 379:2495–2505. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Colombo N, Van Gorp T, Parma G, Amant F,
Gatta G, Sessa C and Vergote I: Ovarian cancer. Crit Rev Oncol
Hematol. 60:159–179. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cancer Stat Facts. Ovarian Cancer.
2020.Available at. https://seer.cancer.gov/statfacts/html/ovary.htmlOctober
10–2023
|
|
9
|
Yeung TL, Leung CS, Yip KP, Au Yeung CL,
Wong ST and Mok SC: Cellular and molecular processes in ovarian
cancer metastasis. A Review in the Theme: Cell and molecular
processes in cancer metastasis. Am J Physiol Cell Physiol.
309:C444–C456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tuxen MK, Sölétormos G and Dombernowsky P:
Tumor markers in the management of patients with ovarian cancer.
Cancer Treat Rev. 21:215–245. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qing X, Liu L and Mao X: A Clinical
diagnostic value analysis of serum CA125, CA199, and HE4 in Women
with early ovarian cancer: Systematic review and meta-analysis.
Comput Math Methods Med. 2022:93393252022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moore LE, Fung ET, McGuire M, Rabkin CC,
Molinaro A, Wang Z, Zhang F, Wang J, Yip C, Meng XY and Pfeiffer
RM: Evaluation of apolipoprotein A1 and posttranslationally
modified forms of transthyretin as biomarkers for ovarian cancer
detection in an independent study population. Cancer Epidemiol
Biomarkers Prev. 15:1641–1646. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schweigert FJ and Sehouli J:
Transthyretin, a biomarker for nutritional status and ovarian
cancer. Cancer Res. 65:11142005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Macuks R, Baidekalna I, Gritcina J,
Avdejeva A and Donina S: Apolipoprotein A1 and transferrin as
biomarkers in ovarian cancer diagnostics. Acta Chirurgica
Latviensis. 10:16–20. 2010. View Article : Google Scholar
|
|
15
|
Giampaolino P, Foreste V, Della Corte L,
Di Filippo C, Iorio G and Bifulco G: Role of biomarkers for early
detection of ovarian cancer recurrence. Gland Surg. 9:1102–1111.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang WL, Lu Z and Bast RC Jr: The role of
biomarkers in the management of epithelial ovarian cancer. Expert
Rev Mol Diagn. 17:577–591. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Muinao T, Deka Boruah HP and Pal M:
Diagnostic and Prognostic Biomarkers in ovarian cancer and the
potential roles of cancer stem cells-An updated review. Exp Cell
Res. 362:1–10. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang F, Zhang Y, Ke C, Li A, Wang W, Yang
K, Liu H, Xie H, Deng K, Zhao W, et al: Predicting ovarian cancer
recurrence by plasma metabolic profiles before and after surgery.
Metabolomics. 14:652018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ashworth T: A case of cancer in which
cells similar to those in the tumours were seen in the blood after
death. Aust Med J. 14:1461869.
|
|
20
|
Yousefi M, Dehghani S, Nosrati R, Ghanei
M, Salmaninejad A, Rajaie S, Hasanzadeh M and Pasdar A: Current
insights into the metastasis of epithelial ovarian cancer-hopes and
hurdles. Cell Oncol. 43:515–538. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Coffman LG, Burgos-Ojeda D, Wu R, Cho K,
Bai S and Buckanovich RJ: New models of hematogenous ovarian cancer
metastasis demonstrate preferential spread to the ovary and a
requirement for the ovary for abdominal dissemination. Transl Res.
175:92–102.e2. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Joosse SA, Gorges TM and Pantel K:
Biology, detection, and clinical implications of circulating tumor
cells. EMBO Mol Med. 7:1–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Giannopoulou L, Kasimir-Bauer S and
Lianidou ES: Liquid biopsy in ovarian cancer: Recent advances on
circulating tumor cells and circulating tumor DNA. Clin Chem Lab
Med. 56:186–197. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu M, Bardia A, Wittner BS, Stott SL, Smas
ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, et al:
Circulating breast tumor cells exhibit dynamic changes in
epithelial and mesenchymal composition. Science. 339:580–584. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fan T, Zhao Q, Chen JJ, Chen WT and Pearl
ML: Clinical significance of circulating tumor cells detected by an
invasion assay in peripheral blood of patients with ovarian cancer.
Gynecol Oncol. 112:185–191. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Van der Auwera I, Peeters D, Benoy IH,
Elst HJ, Van Laere SJ, Prové A, Maes H, Huget P, van Dam P,
Vermeulen PB and Dirix LY: Circulating tumour cell detection: A
direct comparison between the CellSearch System, the AdnaTest and
CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer.
Br J Cancer. 102:276–284. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Su PJ, Wu MH, Wang HM, Lee CL, Huang WK,
Wu CE, Chang HK, Chao YK, Tseng CK, Chiu TK, et al: Circulating
tumour cells as an independent prognostic factor in patients with
advanced oesophageal squamous cell carcinoma undergoing
chemoradiotherapy. Sci Rep. 6:314232016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bankó P, Lee SY, Nagygyörgy V, Zrínyi M,
Chae CH, Cho DH and Telekes A: Technologies for circulating tumor
cell separation from whole blood. J Hematol Oncol. 12:482019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chu PY, Hsieh CH and Wu MH: The
Combination of immunomagnetic bead-based cell isolation and
optically induced dielectrophoresis (ODEP)-based microfluidic
device for the negative selection-based isolation of circulating
tumor cells (CTCs). Front Bioeng Biotechnol. 8:9212020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hsieh JCH and Wu TMH: The selection
strategy for circulating tumor cells (CTCs) isolation and
enumeration: Technical features methods, and clinical applications.
IntechOpen London. 2016.
|
|
31
|
Li SH, Wu MH, Wang HM, Hsu PC, Fang YF,
Wang CL, Chu HC, Lin HC, Lee LY, Wu CY, et al: Circulating EGFR
mutations in patients with lung adenocarcinoma by circulating tumor
cell isolation systems: A concordance study. Int J Mol Sci.
23:106612022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sauerbrei W, Taube SE, McShane LM,
Cavenagh MM and Altman DG: Reporting recommendations for tumor
marker prognostic studies (REMARK): An abridged explanation and
elaboration. J Natl Cancer Inst. 110:803–811. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu CY, Fu JY, Wu CF, Hsieh MJ, Liu YH, Liu
HP, Hsieh JC and Peng YT: Malignancy prediction capacity and
possible prediction model of circulating tumor cells for suspicious
pulmonary lesions. J Pers Med. 11:4442021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gao X, Leow OQY, Chiu CH, Hou MM, Hsieh
JCH and Chao YK: Clinical utility of circulating tumor cells for
predicting major histopathological response after neoadjuvant
chemoradiotherapy in patients with esophageal cancer. J Pers Med.
12:14402022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The eighth edition AJCC cancer staging manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Berek JS, Renz M, Kehoe S, Kumar L and
Friedlander M: Cancer of the ovary, fallopian tube, and peritoneum:
2021 update. Int J Gynaecol Obstet. 155 (Suppl 1):S61–S85. 2021.
View Article : Google Scholar
|
|
37
|
Zuo L, Li X, Zhu H, Li A and Wang Y:
Expression of mir-181a in circulating tumor cells of ovarian cancer
and its clinical application. ACS Omega. 6:22011–22019. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Obermayr E, Reiner A, Brandt B, Braicu EI,
Reinthaller A, Loverix L, Concin N, Woelber L, Mahner S, Sehouli J,
et al: The long-term prognostic significance of circulating tumor
cells in ovarian cancer-A study of the OVCAD consortium. Cancers.
13:26132021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Obermayr E, Braicu EI, Polterauer S,
Loverix L, Concin N, Woelber L, Mahner S, Sehouli J, Van Gorp T,
Vergote I, et al: Association of a combined cancer exhaustion score
with circulating tumor cells and outcome in ovarian cancer-a study
of the OVCAD consortium. Cancers. 13:58652021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kolostova K, Pinkas M, Jakabova A,
Pospisilova E, Svobodova P, Spicka J, Cegan M, Matkowski R and
Bobek V: Molecular characterization of circulating tumor cells in
ovarian cancer. Am J Cancer Res. 6:9732016.PubMed/NCBI
|
|
41
|
Lee M, Kim EJ, Cho Y, Kim S, Chung HH,
Park NH and Song YS: Predictive value of circulating tumor cells
(CTCs) captured by microfluidic device in patients with epithelial
ovarian cancer. Gynecol Oncol. 145:361–365. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Suh DH, Kim M, Choi JY, Bu J, Kang YT,
Kwon BS, Lee B, Kim K, No JH, Kim YB and Cho YH: Circulating tumor
cells in the differential diagnosis of adnexal masses. Oncotarget.
8:771952017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kim M, Suh DH, Choi JY, Bu J, Kang YT, Kim
K, No JH, Kim YB and Cho YH: Post-debulking circulating tumor cell
as a poor prognostic marker in advanced stage ovarian cancer: A
prospective observational study. Medicine (Baltimore).
98:e153542019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kim H, Lim M, Kim JY, Shin SJ, Cho YK and
Cho CH: Circulating tumor cells enumerated by a centrifugal
microfluidic device as a predictive marker for monitoring ovarian
cancer treatment: A pilot study. Diagnostics. 10:2492020.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lou E, Vogel RI, Teoh D, Hoostal S, Grad
A, Gerber M, Monu M, Lukaszewski T, Deshpande J, Linden MA and
Geller MA: Assessment of circulating tumor cells as a predictive
biomarker of histology in women with suspected ovarian cancer. Lab
Med. 49:134–139. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Banys-Paluchowski M, Fehm T, Neubauer H,
Paluchowski P, Krawczyk N, Meier-Stiegen F, Wallach C, Kaczerowsky
A and Gebauer G: Clinical relevance of circulating tumor cells in
ovarian, fallopian tube and peritoneal cancer. Arch Gynecol Obstet.
301:1027–1035. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pearl ML, Dong H, Tulley S, Zhao Q,
Golightly M, Zucker S and Chen WT: Treatment monitoring of patients
with epithelial ovarian cancer using invasive circulating tumor
cells (iCTCs). Gynecol Oncol. 137:229–238. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gening SO, Abakumova TV, Gafurbaeva DU,
Rizvanov AA, Antoneeva II, Miftakhova RR, Peskov AB and Gening TP:
The detection of stem-like circulating tumor cells could increase
the clinical applicability of liquid biopsy in ovarian cancer. Life
(Basel). 11:8152021.PubMed/NCBI
|
|
49
|
Guo YX, Neoh KH, Chang XH, Sun Y, Cheng
HY, Ye X, Ma RQ, Han RPS and Cui H: Diagnostic value of HE4+
circulating tumor cells in patients with suspicious ovarian cancer.
Oncotarget. 9:75222018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Luo HJ, Hu ZD, Cui M, Zhang XF, Tian WY,
Ma CQ, Ren YN and Dong ZL: Diagnostic performance of CA125, HE4,
ROMA, and CPH-I in identifying primary ovarian cancer. J Obstet
Gynaecol Res. 49:998–1006. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chan HT, Chin YM, Nakamura Y and Low SK:
Clonal hematopoiesis in liquid biopsy: From biological noise to
valuable clinical implications. Cancers (Basel). 12:22772020.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Alix-Panabières C and Pantel K:
Circulating tumor cells: Liquid biopsy of cancer. Clin Chem.
59:110–118. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Asante DB, Calapre L, Ziman M, Meniawy TM
and Gray ES: Liquid biopsy in ovarian cancer using circulating
tumor DNA and cells: Ready for prime time? Cancer Lett. 468:59–71.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Diamantopoulou Z, Castro-Giner F and Aceto
N: Circulating tumor cells: Ready for translation? J Exp Med.
217:e202003562020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lin D, Shen L, Luo M, Zhang K, Li J, Yang
Q, Zhu F, Zhou D, Zheng S, Chen Y and Zhou J: Circulating tumor
cells: Biology and clinical significance. Signal Transduct Target
Ther. 6:4042021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Palladini G, Paiva B, Wechalekar A, Massa
M, Milani P, Lasa M, Ravichandran S, Krsnik I, Basset M, Burgos L,
et al: Minimal residual disease negativity by next-generation flow
cytometry is associated with improved organ response in AL
amyloidosis. Blood Cancer J. 11:342021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Nguyen TNA, Huang PS, Chu PY, Hsieh CH and
Wu MH: Recent progress in enhanced cancer diagnosis, prognosis, and
monitoring using a combined analysis of the number of circulating
tumor cells (CTCs) and other clinical parameters. Cancers (Basel).
15:53722023. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Asante DB, Mohan G, Acheampong E, Ziman M,
Calapre L, Meniawy TM, Gray ES and Beasley AB: Genetic analysis of
heterogeneous subsets of circulating tumour cells from high grade
serous ovarian carcinoma patients. Sci Rep. 13:25522023. View Article : Google Scholar : PubMed/NCBI
|
